Press Releases

Moderna and Oxford Secure $60 Million CEPI Funding to Advance Ebola Bundibugyo Vaccine Development During Congo Outbreak

CEPI has committed $60 million to accelerate Ebola Bundibugyo vaccine development with Moderna and the University of Oxford amid an ongoing outbreak in the Democratic Republic of Congo. The funding will support preclinical and early clinical development, along with manufacturing readiness for potential large-scale trials. Health agencies report 282 confirmed cases and 42 deaths, highlighting urgent containment needs. The initiative strengthens global vaccine R&D efforts focused on faster outbreak response and infectious disease preparedness.

Alithea Genomics and Revvity Announce Distribution Agreement to Expand Access to MERCURIUSTM DRUG-seq Solutions

Alithea Genomics has announced a new agreement with Revvity Inc. to broaden access to MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq solutions through Revvity’s global commercial network.

Roche and Nurix Place a Multi-Billion-Dollar Bet on the Future of BTK Degradation

Nurix Therapeutics and Roche have announced a global collaboration to develop and commercialize bexobrutideg, an investigational BTK degrader designed to treat blood cancers, autoimmune disorders, and neurological diseases. Under the agreement, Nurix will receive a $700 million upfront payment and could earn up to $2.3 billion in additional milestone payments. Bexobrutideg is designed to eliminate the BTK protein rather than simply block its activity, potentially offering advantages over existing BTK inhibitors, including effectiveness against treatment-resistant disease. The partnership will support ongoing late-stage studies in chronic lymphocytic leukemia (CLL) while expanding development into multiple sclerosis (MS) and chronic spontaneous urticaria (CSU), aiming to unlock the therapy’s full potential across multiple disease areas.

Baxfendy’s FDA Approval Puts AstraZeneca on Track for a $5 Billion Cardiometabolic Opportunity

AstraZeneca has received FDA approval for Baxfendy, a first-in-class treatment for hypertension, marking a significant milestone in its cardiometabolic growth strategy. The company believes the drug could address a major unmet need among millions of patients with uncontrolled blood pressure and has the potential to generate up to $5 billion in peak annual revenue. AstraZeneca is also evaluating Baxfendy for chronic kidney disease, heart failure, and other related conditions. The approval strengthens the company's position in cardiovascular and metabolic care while supporting its long-term growth ambitions.

Moderna and Merck Report Five-Year Melanoma Data Showing Durable Benefit of Personalized Cancer Vaccine With KEYTRUDA

Moderna and Merck shared 5-year results from the KEYNOTE-942 study showing that their personalized mRNA cancer vaccine, intismeran autogene, combined with KEYTRUDA, significantly improves outcomes for high-risk melanoma patients. The treatment reduced the risk of cancer recurrence or death by 49% and distant metastasis or death by 59% compared to KEYTRUDA alone. It also showed encouraging overall survival trends and stronger immune responses driven by tumor-targeted T-cells. The therapy remained safe over long-term follow-up with mostly mild side effects, highlighting the potential of personalized cancer vaccines in future oncology care.

NextGen Pathology Selects Proscia to Establish AI Foundation for Business Growth

National group positions itself as key partner for biopharmaceutical research, strengthening its role in precision medicine

TeleTracking Brings Real-Time Operational Intelligence Beyond the Hospital Walls with Operations IQ(R) Ambulatory

PrecisionLife strengthens leadership team with appointments of Dr Pradip Banerjee and Dr Kam Pooni

PrecisionLife, a leader in AI-driven precision medicine for chronic diseases, today announced the appointments of Dr Pradip Banerjee, PhD, MBA, as an Independent Non-Executive Director and Dr Kam Pooni, PhD, as Chief Product Officer. These strategic hires further strengthen the company’s leadership as it scales from a pioneering technology innovator to a commercial organization delivering real-world healthcare impact.

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration

CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanized monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months.

CellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Network

CellCarta has announced a Strategic Partnership with Sonic to launch the first commercial laboratory relationship in CellCarta’s Lab Network strategy.

ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection

ClearNote Health today announced a $52M Series D financing alongside the appointment of Kevin Keegan as President and COO.

DNAnexus Scales AI-Driven Capabilities : 17-Year Multiomics Pioneer Powers Next Era of Precision Health

DNAnexus signals a bold new chapter in AI-powered precision health with several new product innovations and solution packages that extend its position as the purpose-built platform where the world's most scientifically complex data becomes the world's most powerful AI fuel.

Baptist Health South Florida and The START Center for Cancer Research Announce Strategic Partnership to Expand Patient Access to Early-Phase Cancer Trials

New START site to be established in collaboration with Baptist Health Herbert Wertheim Cancer Institute will bring novel oncology therapies closer to patients across South Florida.

‘Biopharma innovators must widen CDMO networks to accelerate development’ says Shilpa Biologicals CEO ahead of BIO San Diego

Ahead of BIO San Diego, Shilpa Biologicals urges biotech innovators to engage CDMO partners earlier and look beyond large-scale providers. Over-relying on a narrow network of large CDMOs increases the risk of scope creep, severe clinical trial delays, and budget overruns of up to 40%. Conversely, incorporating smaller CDMOs can lower costs and accelerate timelines from discovery to clinic by several months.

Ambience Healthcare Expands Chart-Aware Intelligence to Full Inpatient Workflow

Building on its chart awareness platform, Ambience now delivers clinical context across the full hospital stay, from admission through discharge

Neuland reports record quarterly revenue of $83M* driven by commercial NCE projects

Quarterly revenue growth up 135% year-on-year, with total revenues passing ₹2000 crore for the first time

Leica Biosystems and CellCarta Expand Collaborative Companion Diagnostic Development Model to Accelerate Commercialization Globally

CellCarta and Leica Biosystems have announced a strategic partnership to bring a proven companion diagnostic (CDx) joint development model from China to biopharma sponsors globally.

Pfizer and Innovent Biologics Enter $10.5 Billion Oncology Drug Development Partnership for 12 Cancer Programs

Pfizer and Innovent Biologics have formed a major oncology partnership worth up to $10.5 billion to develop 12 cancer treatment programs, including antibody-drug conjugates (ADCs) and multispecific antibodies. Pfizer will pay $650 million upfront, with additional milestone-based payments tied to development and commercialization progress. The collaboration combines Innovent’s early-stage research capabilities with Pfizer’s global development and commercialization expertise, aiming to accelerate the delivery of innovative cancer therapies worldwide.

Yourgene Health Launches Insight DPYD Assay

Enhanced pharmacogenetic workflow includes additional variants to support safer, personalised chemotherapy treatment for cancer patients

NGI Becomes First Certified Core Lab and Service Provider for Epigenica’s EpiFinder™ Platforms

Epigenica AB has announced an agreement with the National Genomics Infrastructure, one of the largest technical platforms at SciLifeLab.